Skip to main content


Table 2 Demographics of patients, indicating normal daily therapy and whether they were successfully blinded in this study

From: A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study

ID Age (yrs) Sex GSD type BMI Normal starch treatment Medications Complications Blinding success
A 23 M 1a 21.8 D – 120 g UCCS N –125 g polymer Allopurinol,Ramipril, Carbamazepine Multivitamins Seizures (stable) Yes
B 24 F 1a 26.0 D – 60 g UCCS N – 55 g UCCS Allopurinol, Ramipril. Vit B12 PCOD Renal impairment No – able to tell difference of taste.
C 25 F 1a 26.7 D – UCCS 160 g N - 120 g Polymer Allopurinol Multivitamins PCOD Yes
D 38 M 1a 22.3 D –UCCS 200 g N – UCCS 100 g Allopurinol simvastatin, codeine, lansoprazole Hepatic adenoma (removed) Chronic scar pain Heartburn No – took much less WMHMS than UCCS
E 16 M 1b 27.1 D – 160 g N – 175 g polymer Allopurinol None No – Did not like taste of WMHMS to start but habituated
F 17 M 1b 34.6 D – 120 g N – 140 g polymer Allopurinol Obese Yes – Thought UCCS was test starch.
G 19 F 1b 25 D – 90 g N – 120 g Polymer Allopurinol GCSF Anaemia Recurrent infections No – able to detect different texture
H 18 F 1b 24.9 D – 180 g N – 120 g Allopurinol, GCSF Co-trimoxazole Thalidomide GSD IB enterocolitis Bronchiectasis No – withdrew as did not like taste of WMHMS
I 24 M 1b 19.7 D – 160 g N – 80 g Allopurinol GCSF Short stature Diarrhoea No – took much less WMHMS than UCCS.
J 36 M Ib 22.2 D- 30 g N- 30 g Allopurinol Ferrous sulphate Hepatic adenoma Chronic anaemia No – had fewer episodes of diarrhoea with WMHMS and refused to take UCCS
  1. D = day; N = Night; BMI – Body mass index; GCSF – granulocyte colony stimulating factor; PCOD – poly-cystic ovarian disease.